Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Abstract

The present disclosure provides methods for treating or inhibiting the growth of cancer comprising selecting a patient with cancer and administering a therapeutically effective amount of a LAG-3 inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, the administration of the PD-1 inhibitor enhances the efficacy of a LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in inhibiting the growth of cancer.

Description

technical field [0001] The present disclosure provides, in part, compositions comprising inhibitors of LAG-3 and PD-1 and methods for treating cancer. [0002] sequence listing [0003] An official copy of the Sequence Listing is submitted electronically via EFS-Web as the Sequence Listing in ASCII format in parallel with the description, file name 10568WO01_SEQ_LIST_ST25, date of creation May 12, 2020, and approximately 20 kilobytes in size. The Sequence Listing contained in this ASCII format file is part of the specification and is hereby incorporated by reference in its entirety. Background technique [0004] Programmed death-1 (PD-1) receptor signaling in the tumor microenvironment plays a key role in allowing tumor cells to evade the immune surveillance of the host immune system. The PD-1 receptor has two ligands, PD-ligand-1 (PD-L1) and PD-L2. Blockade of the PD-1 signaling pathway has demonstrated clinical activity in patients with multiple tumor types, and antibo...

AI Technical Summary

Problems solved by technology

Simultaneous targeting of LAG-3 and PD-1, including in anti-PD-1 resistant tumors, may result in objective responses across multiple tumor types in patients

Images